{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:31:41Z","timestamp":1769509901985,"version":"3.49.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stimulatory antiplatelet derived growth factor receptor \u03b1 (PDGFRA) antibodies have been associated with extensive chronic graft-versus-host disease (cGVHD). We performed a phase 1 dose escalation trial of imatinib in corticosteroid-dependent\/refractory cGVHD to assess the safety of imatinib and test the hypothesis that abrogation of PDGFRA signaling can ameliorate the manifestations of cGVHD. Fifteen patients were enrolled. Mean follow-up time was 56.6 weeks (range, 18-82.4 weeks). Imatinib 400 mg daily was associated with more frequent moderate to life-threatening adverse events than 200 mg daily. The main adverse events were nausea, edema, confusion, diarrhea, liver function test elevation, fatigue, and myalgia. The overall response rate was 40% (6 of 15). The treatment failure rate was 40% (6 of 15). Twenty percent (3 of 15) of subjects had stable disease. Of 4 subjects with phospho-PDGFRA and phospho-PDGFRB immunohistochemistry studies before and after treatment, inhibition of phosphorylation was observed in 3 but correlated with response in one. Anti-PDGFRA antibodies were observed in 7 of 11 evaluable subjects but correlated with clinical activity in 4. We conclude that cGVHD responds to imatinib through multiple pathways that may include PDGFRA signal transduction. This study is registered at www.clinicaltrials.gov as #NCT00760981.<\/jats:p>","DOI":"10.1182\/blood-2011-03-341693","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T02:19:18Z","timestamp":1312942758000},"page":"4070-4078","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["A phase 1 study of imatinib for corticosteroid-dependent\/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies"],"prefix":"10.1182","volume":"118","author":[{"given":"George L.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"},{"name":"Department of Medicine\/Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E. D.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington School of Medicine, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne M.","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan C.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Blood and Marrow Transplant, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2019111807190092300_B1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.bloodjournal572267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"issue":"2","key":"2019111807190092300_B2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients.","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"1","key":"2019111807190092300_B3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation: Late Effects Working Committee of the International Bone Marrow Transplant Registry.","volume":"341","author":"Socie","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807190092300_B4","first-page":"319","article-title":"Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning.","volume":"11","author":"Syrjala","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111807190092300_B5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease.","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111807190092300_B6","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2002.06.077","article-title":"Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.","volume":"20","author":"Kiss","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807190092300_B7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1365-2141.2000.02053.x","article-title":"Quality of life in 244 recipients of allogeneic bone marrow transplantation.","volume":"110","author":"Chiodi","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111807190092300_B8","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111807190092300_B9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.bmt.1703677","article-title":"Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.","volume":"30","author":"Worel","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111807190092300_B10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"issue":"1","key":"2019111807190092300_B11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111807190092300_B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease.","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111807190092300_B13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111807190092300_B14","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111807190092300_B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2004.10.004","article-title":"Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.","volume":"11","author":"Johnston","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111807190092300_B16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease.","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"issue":"25","key":"2019111807190092300_B17","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111807190092300_B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2019111807190092300_B19","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1002\/1529-0131(200111)44:11<2653::AID-ART445>3.0.CO;2-1","article-title":"Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.","volume":"44","author":"Sambo","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2019111807190092300_B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000111507","article-title":"The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.","volume":"216","author":"Soria","year":"2008","journal-title":"Dermatology"},{"issue":"11","key":"2019111807190092300_B21","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111807190092300_B22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111807190092300_B23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"2019111807190092300_B24","volume-title":"Gleevec (imatinib mesylate) tablets prescribing information","year":"2006"},{"issue":"10","key":"2019111807190092300_B25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807190092300_B26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study.","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"2019111807190092300_B27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"1","key":"2019111807190092300_B28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111807190092300_B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111807190092300_B30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111807190092300_B31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features.","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111807190092300_B32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"issue":"27","key":"2019111807190092300_B33","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1200\/JCO.2007.10.8456","article-title":"Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.","volume":"25","author":"Jacobsohn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807190092300_B34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111807190092300_B35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2009.84","article-title":"Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD.","volume":"44","author":"Jacobsohn","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111807190092300_B36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis.","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2019111807190092300_B37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2019111807190092300_B38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2019111807190092300_B39","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111807190092300_B40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2019111807190092300_B41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807190092300_B42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4070\/1342406\/zh804111004070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/15\/4070\/1342406\/zh804111004070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:22:32Z","timestamp":1574079752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/15\/4070\/29054\/A-phase-1-study-of-imatinib-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2011,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-341693","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}